J&J : RYBREVANT LAZCLUZE Outperforms Osimertinib In Phase 3 Trial For EGFR-Mutated Lung Cancer

(RTTNews) - Johnson & Johnson (JNJ) announced results for the gold standard endpoint in cancer treatment of overall survival or OS from the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib showed RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) signi https://www.nasdaq.com/articles/jj-rybrevant-lazcluze-outperforms-osimertinib-phase-3-trial-egfr-mutated-lung-cancer